Sarepta (SRPT) Sees Modest Selling Amid $225M Stock Offering
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) is down just 0.7% on plans to offer $225 million in common stock. The stock has more than doubled this week after announcing FDA approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ContraVir Pharma (CTRV) Gains on Heavy Volume
- CBOE (CBOE) Announces New SPX Options Implied Volatility-Based Index: SMILE
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesEquity Offerings, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!